Company news

Ocugen, Inc. news in 2024

Ocugen, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

December 18, 2024

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

November 26, 2024

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

November 19, 2024

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

November 18, 2024

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

November 7, 2024

Ocugen Secures $30 Million in Debt Funding

November 6, 2024

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

October 27, 2024

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

October 21, 2024

Ocugen to Host Conference Call on Friday, November 8 at 8: 30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

October 16, 2024

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

October 9, 2024

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

October 8, 2024

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

October 1, 2024

Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference

September 23, 2024

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

September 8, 2024

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

September 4, 2024

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

August 27, 2024

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

August 25, 2024

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

August 7, 2024

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

August 4, 2024

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

August 1, 2024

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

July 30, 2024

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

July 30, 2024

Ocugen to Host Conference Call on Thursday, August 8 at 8: 30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

July 28, 2024

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

July 24, 2024

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

June 20, 2024

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

June 19, 2024

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

May 30, 2024

Ocugen to Present at BIO International Convention 2024

May 28, 2024

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

May 27, 2024

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

May 19, 2024

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

May 14, 2024

Ocugen Provides Business Update with First Quarter 2024 Financial Results

May 13, 2024

Ocugen to Present at May 2024 Investor Conferences

May 9, 2024

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

May 9, 2024

Ocugen to Host Conference Call on Tuesday, May 14 at 8: 30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

May 2, 2024

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

May 1, 2024

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

April 28, 2024

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

April 25, 2024

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

April 18, 2024

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

April 11, 2024

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

April 9, 2024

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

April 7, 2024

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

April 4, 2024

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

April 1, 2024

Ocugen to Host Conference Call on Tuesday, April 2 at 8: 30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

March 31, 2024

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

March 31, 2024

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

March 17, 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

March 12, 2024

Ocugen to Present at Investing in Cures Summit

March 5, 2024

Older news releases →

Calls in 2024

Decks in 2024